13D Filing: PTV Sciences II LP and Apollo Endosurgery Inc. (APEN)

Page 16 of 21

Page 16 of 21 – SEC Filing


Other than as described above in this Item 4, none of the Reporting Persons have any plan or proposal
relating to or that would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or
liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) any change in the present board of directors or management of the Issuer,
including any plans or proposals to change the number or terms of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material
change in the Issuers business or corporate structure; (g) any changes in the Issuers charter, by-laws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;
(h) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class
of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act; or (j) any action similar to those enumerated above.

Item 5. Interest in Securities of the Issuer

The following information with respect to the ownership of the
Common Stock of the Issuer by the Reporting Persons is provided as of September 19, 2017:

Reporting Person

Shares Held
Directly
Sole Voting
Power
Shared
Voting
Power (1)
Sole
Dispositive
Power
Shared
Dispositive
Power (1)
Beneficial
Ownership
Percentage
of Class (2)

PTV II

2,199,186 0 5,419,372 0 5,419,372 5,419,372 31.4 %

PTV IV

1,347,565 0 5,419,372 0 5,419,372 5,419,372 31.4 %

PTV SO

605,712 0 5,419,372 0 5,419,372 5,419,372 31.4 %

PTV EG

1,266,909 0 5,419,372 0 5,419,372 5,419,372 31.4 %

PTV GP II

0 0 5,419,372 0 5,419,372 5,419,372 31.4 %

PTV GP IV

0 0 5,419,372 0 5,419,372 5,419,372 31.4 %

PTV GP SO

0 0 5,419,372 0 5,419,372 5,419,372 31.4 %

PTV GP EG

0 0 5,419,372 0 5,419,372 5,419,372 31.4 %

PTV GP Management II

0 0 5,419,372 0 5,419,372 5,419,372 31.4 %

PTV GP Management IV

0 0 5,419,372 0 5,419,372 5,419,372 31.4 %

Crawford

45,454 45,454 5,419,372 45,454 5,419,372 5,464,826 31.7 %

Anderson

45,454 45,454 5,419,372 45,454 5,419,372 5,464,826 31.7 %
(1) Includes 2,199,186 shares of Common Stock held by PTV II, 1,347,565 shares of Common Stock held by PTV IV, 605,712 shares held by PTV SO and 1,266,909 shares held by PTV EG.

PTV GP Management II is the sole general partner of PTV GP II, which is the sole general partner of PTV II. PTV GP Management II and PTV GP II
own no securities of the Issuer directly and share power to vote and dispose of the shares held by PTV II.

PTV GP Management IV is
(i) the sole general partner of PTV GP IV, which is the sole general partner of PTV IV, (ii) the sole general partner of PTV GP SO, which is the sole general partner of PTV SO, and (iii) the sole general partner of PTV GP EG, which is
the sole general partner of PTV EG. PTV GP Management IV and PTV GP IV own no securities of the Issuer directly and share power to vote and dispose of the shares held by PTV IV. PTV GP Management IV and PTV GP SO own no securities of the Issuer
directly and share power to vote and dispose of the shares held by PTV SO. PTV GP Management IV and PTV GP EG own no securities of the Issuer directly and share power to vote and dispose of the shares held by PTV EG.

Crawford and Anderson are managers of PTV GP Management II and PTV GP Management IV. Accordingly, Crawford and Anderson may be deemed to share
power to vote and dispose of the shares held by PTV II, PTV IV and PTV SO (collectively, the PTV Funds).

(2) This percentage is calculated based upon an estimated 17,252,299 shares of the Issuers common stock outstanding as of July 26, 2017, as reported by the Issuer in the Form 10-Q filed with the SEC on
August 1, 2017.

Page 16

Follow Apollo Endosurgery Inc. (NASDAQ:APEN)

Page 16 of 21